Summary N-(4-hydroxyphenyl) retinamide (4-HPR) is a synthetic retinoid which reduces the incidence of experimental tumours in animals and has been chosen for its weak toxicity to be tested as a chemopreventive agent in humans. The mechanism of antineoplastic action is still unknown but a possible immunoenhancing effect may be postulated. We investigated the NK activity of PBMC from a group of women treated with 4-HPR as a part of a large scale randomised phase III trial on chemoprevention of controlateral disease in mastectomised women. After 180 days of treatment the NK activity was augmented 1.73 times as compared to that of patients given a placebo. The NK activity of PBMC from 4-HPR treated women is maximised, being higher than the basal and even the rIL-2 or alfa-rIFN stimulated activity of controls. For this reason in the majority of cases it cannot be further augmented by incubation with either rIL-2 or alfa-rIFN in vitro. The increased NK activity of 4-HPR treated women is not due to an enhanced production of endogenous IL-2, because PBMC cultures from patients treated with 4-HPR or placebo, incubated in vitro with a panel of different stimulators (recall antigens, PHA, allogeneic and xenogeneic cells) produce similar amounts of IL-2. The functional activity, but not the number of NK cells is increased in 4-HPR treated women. The mechanism by which 4-HPR stimulates NK activity is not a function of direct action on NK cells. Indeed incubation of PBMC from blood donors with 4-HPR or its major metabolite N-(4-methoxyphenyl) retinamide (4-MPR) does not modify their natural cytotoxicity.
Vitamin A (Retinol) and some of its naturally occurring or synthetic analogues or derivatives (Retinoids) exhibit antineoplastic activity against epithelial tumours induced by chemical carcinogens in vivo or in vitro. Inhibition of the growth and development of transplantable tumours both in vivo and in vitro has also been demonstrated. Unfortunately, clinical use of these compounds in the prevention and treatment of human cancers has been slowed because of their toxicity. For this reason, over 2000 synthetic analogues of retinoids have been produced and N-(4-hydroxyphenyl) retinamide (4-HPR) appeared to be one of a few that has retained the beneficial therapeutic effect with reduced toxicity. In particular, 4-HPR inhibits the development of breast cancer induced in rats by N-methyl-N-nitrosourea, and it is not stored in the liver, so that hepatotoxicity that results from the feeding of other chemopreventive retinoids is not likely to occur (Hultin et al., 1986) .
The aforementioned characteristics of 4-HPR led to its use for the prevention of controlateral disease in breast cancer patients with no axillary lymph node metastases who previously underwent radical surgery. In March 1987, a large scale randomised phase III trial was started at the Istituto Nazionale Tumori of Milano. The protocol planned a 5-year 4-HPR administration at 200 mg/day p.o., including a 3-day drug interruption at the end of each month, vs a control group receiving a placebo. Details of this trial are reported elsewhere (Rotmensz et al., 1991) . The mechanism by which 4-HPR prevents mammary cancer, at least in rodents, is still unknown, although it has been reported that vitamin A and Retinoids may modulate both cellular immunity and cytotoxicity mediated by natural killer (NK) cells. Several papers indicate an important in vivo role for NK cells in tumour resistance but, as far as we know, their activity in 4-HPR treated women has not yet been studied.
The experiments described in this study demonstrate that the natural cytotoxicity of peripheral blood mononuclear cells (PBMC) is significantly (P <0.005) higher in 4-HPR treated women than in controls, i.e. mastectomised women receiving a placebo, and that it is maximised. Indeed, incubation of their PBMC with rIL-2 and alfa-rIFN, which usually augments the NK activity in vitro, did not further increase natural cytotoxicity, as opposed to that of controls. It has also been demonstrated that the functional acitivity, but not the number of NK cells is increased in 4-HPR treated women and that such an increase is independent from IL-2 blood levels. Although it seems likely that 4-HPR acts through some of its metabolites, the experiments so far carried out with the major and only one available at present for experimental purposes (N-(4-methoxyphenyl) Some tubes were used for PBMC separation as described elsewhere (Villa et al., 1991) . Some other tubes, wrapped in aluminium foil to prevent exposure to light, were centrifuged at 1500 g for 15 min at 4°C and plasma, separated in the dark, was kept frozen at -20°C until analytical procedures for no more than 3 weeks. (Formelli et al., 1989) .
Calculations and statistical analysis of data Student's t-tests were performed for the comparison of two independent samples of unequal size as described by Snedecor & Cochran (1980) Figure 1 and was as follows: (1) Healthy controls . The per cent increase was less marked in 4-HPR treated women because their basal activity at this time was higher and, in some cases, already near to the maximum. Indeed, even before IL-2 stimulation, only 6/17 cases showed an activity under, and as many as 11/17 above the normal IL-2 stimulated threshold.
Incubation with IL-2 increased the NK activity of the former six cases above stimulated threshold, leaving almost unvaried the activity of the later 11 cases. PBMC from all but one placebo treated women, after IL-2 incubation, showed an activity above the normal IL-2 stimulated threshold.
The responsiveness to alfa-rIFN was less marked; the basal vs IFN activated cytotoxicity expressed as percentage lysis ± s.d. was equal to 48.36 ± 15.96 vs 63.63 ± 18.03 (32% increase) for placebo patients, to 60.13 ± 11.08 vs 83.6 ± 9.85 (39% increase) for blood donors and to 70.35 ± 20.49 vs 80.05 ± 13.15 for 4-HPR treated women (14% increase).
As far as concerns individual patterns, the basal NK activity in 4-HPR treated women was already up to the alfa-rIFN stimulated threshold of blood donors in 12/17 cases; following incubation 16/17 cases went above the alfarIFN stimulated threshold. On the other hand, only 5/11 placebo treated patients, after the incubation with alfa-rIFN, showed a NK activity above the normal activated threshold.
In summary it appears that PBMC from blood donors and placebo treated women behave almost in the same way and are more stimulated after incubation with rIL-2 than with alfa-rIFN. The NK activity of PBMC from 4-HPR treated women is already maximised in most cases and can no longer be significantly increased by incubation with either one of the two cytokines.
IL-2 production To test the ability of PBMC to produce IL-2 in vitro in response to different stimulators, PBMC were cultured for 7 days with FLU, ALLO, PHA and XENO, in presence of the MoAb anti-IL-2 receptor, to prevent IL-2 consumption. At the end of culture period the supernatants were harvested and tested for IL-2 content by assessing their capacity to support the proliferation of the IL-2 dependent CTLL cell line; normalised IL-2 responses expressed as absolute c.p.m., supernatant dilution of 1:4 has been utilised for calculation. The results, as shown in Table I , show that IL-2 production by PBMC of 4-HPR treated patients is unvaried as compared to that of placebo treated patients and blood donors. Figure 4 , which shows that neither 4-HPR nor 4-MPR modify the NK activity of PBMC.
Discussion
The results of this study demonstrate that the expression of human natural cytotoxicity is modulated in vivo by effect of long term administration p.o. of the putative anti-tumour agent 4-HPR. As shown in Figure 1 , the basal NK activity of mastectomised women treated for 6 months with 4-HPR, was augmented about 1.73 times as compared to that of blood donors from our Institute. These findings are in agreement with other reports showing that: (1) wild type BALB/c mice given retinol only had a NK activity about 1.16 times higher than that of controls (Fraker et al., 1986) and, (2) vegetarians have a blood carotene (provitamin A) concentration and a NK activity significantly higher, by a factor of 2.0, than that of their omnivorous controls. This enhanced natural cytotoxicity may be one of the factors contributing to the lower cancer risk shown by vegetarians (Malter et al., 1989) . Some controversial data are reported by Jemma et al. (1986) , who refers that feeding retinol to man and mice brings about an augmentation of NK activity in the murine model but not in humans. Toads fed retinoic acid have enhanced NK activity in comparison with untreated controls (Sadek et al., 1987) . In contrast, preincubation of toad PBMC in vitro with retinoic acid did not modify the activity of NK cells.
Treatment of human and mouse PBMC with retinol and retinoids in vitro has been studied with some degree of controversy concerning increase (McCormick et al., 1985; Jemma et al., 1986) or invariability (Sadek et al., 1987; Sidell et al., 1985) in NK cell activity. In summary it may be stated that, with few exceptions, in vivo administration of retinol and retinoids, but not in vitro preincubation with the same com- (Fraker et al., 1986; McCormick et al., 1985) (Figure 2 ), while the increase in the NK activity due to oral retinol administration is dose-dependent, at least in the murine models (Jemma et al., 1986) . and correlates with an increased blood retinol concentration (Fraker et al., 1986) . It has also been reported that addition of 4-HPR to human plasma at 37°C in vitro does not cause a change in the endogenous plasma retinol or RBP levels, indicating that there is no direct chemical interaction between 4-HPR and retinol or RBP (Peng et al., 1989) . Therefore, we performed some experiments on 4-HPR, and 4-MPR incubation of PBMC from blood donors in order to ascertain its influence on the natural cytotoxicity in vitro. The NK activity is never statistically different from that of controls in both cases. Following incubation with rIL-2 and alfa-rIFN the NK cell activity of PBMC from 4-HPR treated women showed only a 27% and 14% increase over the basal cytotoxicity, respectively. In contrast, rIL-2 and alfa-rIFN incubation of PBMC from placebo treated women and blood donors caused a sharp 79% and 46% increase of NK activity over the basal cytotoxicity, respectively.
The basal NK activity of PBMC from 4-HPR treated women was already up to the basal or rIL-2 and alfa-rIFN stimulated threshold in the vast majority of cases and, therefore, could no longer be significantly augmented by incubation with either one of the cytokines in vitro. The opposite is true for PBMC from placebo treated women and blood donors, whose NK activity was markedly increased by r-1L2 and alfa-rIFN incubation in vitro, as it is summarised in Figure 3 . There are no reports, as far as we know, about the influence of IL-2 incubation of PBMC from humans or laboratory animals treated with retinol or retinoids. However our findings suggesting that NK activity of PBMC from 4-HPR treated women in most cases is maximised agrees with the observation by Fraker et al. (1986) It is possible to hypothesise that the high basal cytotoxicity of NK cells from 4-HPR treated women could be a function of an increased production of endogenous IL-2. Therefore, the amount of IL-2 produced by PBMC stimulated in vitro was measured by means of a proliferation assay of a IL-2 dependent cell line (CTLL). We evaluated the IL-2 production following stimulation with FLU, ALLO, PHA and XENO, as specified in Methods. This panel of stimuli was selected because it permits the analysis of several T helper/ Antigen Presenting Cell (Th/APC) pathways. The responses to FLU and XENO require CD4+ Th and autologous APC. Responses to ALLO can utilise both CD4+ and CD8+ Th together with allogeneic or autologous APC; in contrast, the response to PHA utilises both CD4+ and CD8+ Th, but is less dependent on APC. The results reported in Table I show that IL-2 production of PBMC cultures from patients treated with 4-HPR or placebo is not significantly different prior and after 180 days of treatment.
From the present data, it may be concluded that: (1) the NK activity of mastectomised women treated for 180 days with 4-HPR is significantly higher than that of those receiving a placebo, (2) the functional activity, but not the number, of NK cells is increased in 4-HPR treated women, (3) the basal NK activity of PBMC from 4-HPR treated women is maximised because, being higher than the basal or rIL-2 and alfa-rIFN stimulated thresholds in the vast majority of cases, cannot be further augmented by incubation with either rIL-2 or alfa-rIFN in vitro, (4) IL-2 production of PBMC cultures from patients treated with 4-HPR or placebo is not significantly different prior to and after 180 days of treatment; in other words, the increased NK activity of 4-HPR treated women is not a function of an increased production of endogenous IL-2, (5) incubation of PBMC of blood donors with 4-HPR does not modify their natural cytotoxicity, thus showing that such retinoid is active in vivo but not in vitro, and (6) 4-HPR is not acting through its major metabolite 4-MPR.
It is therefore of both biologic interest and of potential significance that 4-HPR enhances natural killer cell cytotox- .-icity, since this activity may be an important component of the antineoplastic effect of synthetic retinoid.
